JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Cogent Biosciences (NASDAQ:COGT) and increased the price target from $18 to $20.
February 27, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama reaffirmed an Overweight rating on Cogent Biosciences and raised the price target from $18 to $20.
The upgrade in the price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100